INLEXZO (Gemcitabine Hydrochloride) Patent Expiration, LOE Window & CMS Spending
INLEXZO (Gemcitabine Hydrochloride) by Johnson & Johnson: FDA Orange Book core substance LOE 2034-08-19 (last listed 2038-11-07), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $69,000 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Johnson & Johnson |
| FDA Application & Pathway | N219683 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2034-08-19 |
| Last Listed Patent or Exclusivity Date | 2038-11-07 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($69,000 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.